



informed that the hybrid cell line was deposited under restriction and has not been released to the public. Also cited in the IDS are other references that mention monoclonal antibody PEQ226; Dillman R.O et al., "Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies", Cancer Biotherapy, 9(1):17-28 (1994); Dillman et al., "Toxicities associated with monoclonal antibody infusions in cancer patients." Molecular Biother, 1:81-85 (1988); Leung, J., et al., "Selection of a monoclonal antibody to a new prostate cancer marker for in vivo clinical trials" (abstract) 6<sup>th</sup> Int. Congr. Immunol., p. 516 (1986); and Wang et al., "Monoclonal Antibody Assays for Prostatic Tumor", Immunol Ser 39:195-219 (1988).

Applicant's submission of the items identified in this IDS is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR Section 1.97(h)), or even qualifies as "prior art" under 35 USC Section 102 with respect to the instant invention.

It is submitted that this IDS is timely as being filed with the concurrently filed Request for Continued Examination (RCE).

Respectfully submitted,

LYON & LYON LLP

Dated: September 18, 2001

By: 

Lois M. Kwasigroch  
Reg. No. 35,579

633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
(213) 489-1600

Enclosures: Form PTO-1449 and copies of references cited therein